Chemoradiotherapy in malignant glioma: Standard of care and future directions

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4127-4136

  Stupp, Roger ^a   Hegi, Monika E ^a   Gilbert, Mark R ^a   Chakravarti, Arnab ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BANOXANTRONE; BEVACIZUMAB; CETUXIMAB; CILENGITIDE; COTRIMOXAZOLE; DAPSONE; ENZASTAURIN; EVEROLIMUS; HYDROXYUREA; IMATINIB; LENALIDOMIDE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLGUANINE METHYLTRANSFERASE; METHYLGUANINE METHYLTRANSFERASE INHIBITOR; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PENTAMIDINE; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; VATALANIB;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANDIDIASIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL MIGRATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DNA METHYLATION; DNA REPAIR; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENETIC EPIGENESIS; GLIOBLASTOMA; GLIOMA; HERPES; HUMAN; KAPOSI SARCOMA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BRAIN TUMOR; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS;

EID: 34748884398     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8554     Document Type: Review

References (100)

1. Seiwert TY, Salama JK, Vokes EE: The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4:86-100, 2007
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
3. Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030, 1999
4. Ostermann S, Csajka C, Buclin T, et al: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728-3736, 2004
5. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
6. Brada M, Hoang-Xuang K, Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001
7. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
8. Newlands E, Wedge S, Porteous J, et al: Temozolomide: Drug scheduling in vivo and in combination with radiation. Proc Am Soc Clin Oncol 16:393a, 1997 (abstr 1403)
9. Brock CS, Newlands ES, Wedge SR, et al: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363-4367, 1998
10. Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of 06-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011, 2003
11. Wick A, Feisberg J, Steinbach JP, et al: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361, 2007
12. Wick W, Weller M: How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 23:4235-4236, 2005
13. Newlands ES, Stevens MF, Wedge SR, et al: Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61, 1997
14. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585-2597, 2000
15. Stupp R, Gander M, Leyvraz S, et al: Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol 2:552-560, 2001
16. Mutter N, Stupp R: Temozolomide: A milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6:1187-1204, 2006
17. Kaina B, Ziouta A, Ochs K, et al: Chromosomal instability, reproductive cell death and apoptosis induced by 06-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: Facts and models. Mutat Res 381:227-241, 1997
18. Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963, 2001
19. Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849, 2001
20. Hirose Y, Kreklau EL, Erickson LC, et al: Delayed repletion of 06-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg 98:591-598, 2003
21. Caporali S, Falcinelli S, Starace G, et al: DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol Pharmacol 66:478-491, 2004
22. Hall E, Giaccia R: Radiobiology for the Radiologist, 2005 (ed 6). New York, Lippincott Williams & Wilkins
23. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006
24. Stupp R, Hegi ME: Targeting brain-tumor stem cells. Nat Biotechnol 25:193-194, 2007
25. Wedge SR, Porteous JK, Glaser MG, et al: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97, 1997
26. van Rijn J, Heimans JJ, van den Berg J, et al: Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47:779-784, 2000
27. Chakravarti A, Erkkinen MG, Nestler U, et al: Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 12:4738-4746, 2006
28. Wild-Bode C, Weller M, Rimner A, et al: Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma. Cancer Res 61:2744-2750, 2001
29. Zhai GG, Malhotra R, Delaney M, et al: Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 76:227-237, 2006
30. Abdollahi A, Griggs DW, Zieher H, et al: Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11:6270-6279, 2005
31. Wick W, Wick A, Schulz JB, et al: Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62:1915-1919, 2002
32. Stupp R, Dietrich P, Ostermann Kraljevic S, et al: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382, 2002
33. Stupp R, Hegi ME: Recent developments in the management of malignant glioma, in Perry M (ed): ASCO 2003 Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2003, pp 779-788
34. Athanassiou H, Synodinou M, Maragoudakis E, et al: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372-2377, 2005
35. Bell J, Brady MF, Young RC, et al: Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 102:432-439, 2006
36. Combs SE, Gutwein S, Schulz-Ertner D, et al: Temozolomide combined with irradation as postoperative treatment of primary glioblastoma multiforme: Phase I/II study. Strahlenther Onkol 181:372-377, 2005
37. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
38. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
39. Westeel V, Quoix E, Moro-Sibilot D, et al: Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97:499-506, 2005
40. Muss HB, Case LD, Richards F 2nd, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
41. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
42. Mahindra AK, Grossman SA: Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 63:263-270, 2003
43. Su YB, Sohn S, Krown SE, et al: Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications. J Clin Oncol 22:610-616, 2004
44. Ganière V, Christen G, Bally F, et al: Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 3:339-343, 2006
45. Kovacs JA, Masur H: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342:1416-1429, 2000
46. Ochs K, Kaina B: Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60:5815-5824, 2000
47. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388-2399, 2002
48. Gerson SL: MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307, 2004
49. Jagtap P, Szabo C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440, 2005
50. Grombacher T, Mitra S, Kaina B: Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 17:2329-2336, 1996
51. Esteller M, Hamilton SR, Burger PC, et al: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797, 1999
52. Jaeckle KA, Eyre HJ, Townsend JJ, et al: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J Clin Oncol 16:3310-3315, 1998
53. 6-aklylgunaine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857, 1998
54. Brell M, Tortosa A, Verger E, et al: Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167-5174, 2005
55. Stupp R, Hegi ME: Methyl-guanine methyltransferase testing in glioblastoma: When and how? J Clin Oncol 25:1459-1460, 2007
56. Lefebvre P, Laval F: Enhancement of O6-methylguanine-DNA- methyltransferase activity induced by various treatments in mammalian cells. Cancer Res 46:5701-5705, 1986
57. Qian XC, Brent TP: Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672-3677, 1997
58. Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
59. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874, 2004
60. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
61. Lee SM, Thatcher N, Crowther D, et al: Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69:452-456, 1994
62. Stupp R, Hegi ME, van den Bent MJ, et al: Changing paradigms: An update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180, 2006
63. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
64. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006
65. Möllemann M, Wolter M, Felsberg J, et al: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005
66. Brandes AA, Tosoni A, Cavallo G, et al: Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study. J Clin Oncol 24:4746-4753, 2006
67. Shaw E, Berkey B, Coons S, et al: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG). J Clin Oncol 24:58s, 2006 (suppl; abstr 1500)
68. van den Bent MJ, Afra D, de Witte O, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366:985-990, 2005
69. Stupp R, Janzer RC, Hegi ME, et al: Prognostic factors for low-grade gliomas. Semin Oncol 30:23-28, 2003
70. Stupp R, Baumert BG: Promises and controversies in the management of low-grade glioma. Ann Oncol 14:1695-1696, 2003
71. Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22:1926-1933, 2004
72. Rich JN, Bigner DD: Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430-446, 2004
73. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004
74. Raizer JJ, Abrey LE, Wen P, et al: A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant glioma not on EIAEDs. J Clin Oncol22:107s, 2004 (suppl; abstr 1502)
75. Prados MD, Lamborn KR, Chang S, et al: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 8:67-78, 2006
76. van den Bent M, Brandes A, Rampling R, et al: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. J Clin Oncol 25:76s, 2007 (suppl; abstr 2005)
77. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005
78. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024, 2005
79. Lassman AB, Rossi MR, Razier JR, et al: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin Cancer Res 11:7841-7850, 2005
80. Pelloski C, Ballman K, Furth A, et al: Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25:2288-2294, 2007
81. Chakravarti A, Berkey B, Robins H, et al: An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 24:64s, 2006 (suppl; abstr 1527)
82. Heimberger A, Hussain S, Aldape K, et al: Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol 24:107s, 2006 (suppl; abstr 2529)
83. Fine HA, Kim L, Royce C, et al: Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 23:115s, 2005 (suppl; abstr 1504)
84. Tabatabai G, Frank B, Wick A, et al: Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 61:153-161, 2007
85. Feldkamp MM, Lau N, Roncari L, et al: Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 61:4425-4431, 2001
86. Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18:7514-7526, 1999
87. Wang CC, Liao YP, Mischel PS, et al: HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res 66:6756-6762, 2006
88. Gilbert M, Hess K, Groves MD, et al: A phase I study of temozolomide and the farnesyltransferase inhibitor, tipifarnib in recurrent glioblastoma: A dose and schedule intensive regimen. Neuro-oncol 6:375, 2004 (abstr)
89. Goudar RK, Shi Q, Hjelmeland MD, et al: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101-112, 2005
90. Chang SM, Wen P, Cloughesy T, et al: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361, 2005
91. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005
92. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007
93. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
94. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
95. Brandes A, Stupp R, Hau P, et al: EORTC Study 26041-22041 Phase I/II study on concomitant and adjuvant zemozolomide (TMZ) and tadiotherapy with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma: Results of Phase I. J Clin Oncol 25:81s, 2007 (suppl; abstr 2026)
96. Wachsberger PR, Burd R, Marero N, et al: Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835-842, 2005
97. Alghisi GC, Ruegg C: Vascular integrins in tumor angiogenesis: Mediators and therapeutic targets. Endothelium 13:113-135, 2006
98. Stupp R, Ruegg C: Integrin inhibitors reaching the clinic. J Clin Oncol 25:1637-1638, 2007
99. Nabors B, Mikkelsen T, Rosenfeld S, et al: A phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657, 2007
100. Stupp R, Goldbrunner R, Neyns B, et al: Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 25:75s, 2007 (suppl; abstr 2000)